[Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
BACKGROUND
Survival and clinical course were unknown in patients with recurrence of para-aortic lymph node after curative D2 gastrectomy and adjuvant S-1 chemotherapy.


METHODS
The study examined clinical characteristics and prognosis of 3 patients who had para-aortic nodal recurrence after curative D2 gastrectomy and S-1 adjuvant chemotherapy.


RESULTS
Initial stage was III C in all of the patients. Median treatment interval of S-1 was 8 . 8 months. Para-aortic nodal metastasis was single in 2 and multiple in 1 patient. Median survival time was 14 .3 months. Other recurrent sites than para- aortic node were not seen in all of the patients.


CONCLUSIONS
In the times of S-1 adjuvant chemotherapy, it is valuable to know whether para-aortic node should be resected prophylactically, or be treated after recurrence, or be treated by locally or systemically.
Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
Toru
T
Aoyama
Takaki
T
Yoshikawa
Tsutomu
T
Hayashi
Hiroshi
H
Kuwabara
Yo
Y
Mikayama
Takashi
T
Ogata
Haruhiko
H
Cho
Akira
A
Tsuburaya
Yasushi
Y
Rino
Munetaka
M
Masuda
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001011:Aorta; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid